Krilogy Financial LLC Acquires New Shares in Exelixis, Inc. $EXEL

Key Points

• Krilogy Financial LLC has bought a new position in Exelixis, Inc. by acquiring 10,349 shares worth approximately $456,000 during the 2nd quarter.
• Exelixis reported a quarterly earnings per share (EPS) of $0.75, exceeding analysts' estimates, though revenue declined by 10.8% compared to the previous year.
• Thirteen analysts rate Exelixis as a Moderate Buy, with a consensus price target of $44.06 amidst recent changes in ratings from various financial institutions.

Krilogy Financial LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,349 shares of the biotechnology company's stock, valued at approximately $456,000.

Several other large investors also recently bought and sold shares of EXEL. Janus Henderson Group PLC boosted its position in shares of Exelixis by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 124,905 shares of the biotechnology company's stock worth $4,160,000 after purchasing an additional 1,558 shares in the last quarter. Quantinno Capital Management LP bought a new position in Exelixis in the 4th quarter worth approximately $559,000. State of Wyoming boosted its position in shares of Exelixis by 357.4% during the 4th quarter. State of Wyoming now owns 12,360 shares of the biotechnology company's stock valued at $412,000 after purchasing an additional 9,658 shares in the last quarter. Tidal Investments LLC boosted its position in shares of Exelixis by 187.8% in the fourth quarter. Tidal Investments LLC now owns 104,665 shares of the biotechnology company's stock worth $3,485,000 after buying an additional 68,299 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of Exelixis by 56.4% in the 4th quarter. Two Sigma Investments LP now owns 1,328,553 shares of the biotechnology company's stock valued at $44,241,000 after purchasing an additional 478,889 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on EXEL. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 26th. Truist Financial dropped their price target on Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Jefferies Financial Group set a $50.00 target price on shares of Exelixis and gave the company a "buy" rating in a research report on Tuesday, June 24th. UBS Group set a $38.00 target price on shares of Exelixis and gave the company a "neutral" rating in a research report on Wednesday, July 30th. Finally, Morgan Stanley lifted their target price on Exelixis from $46.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $44.42.

Exelixis Stock Down 0.9%

Shares of EXEL traded down $0.35 during mid-day trading on Friday, reaching $40.10. The company's stock had a trading volume of 7,751,452 shares, compared to its average volume of 2,270,912. The business has a fifty day moving average of $39.52 and a 200 day moving average of $39.69. The company has a market cap of $10.79 billion, a price-to-earnings ratio of 19.28, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32. Exelixis, Inc. has a 1 year low of $25.17 and a 1 year high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. During the same quarter in the prior year, the firm earned $0.84 EPS. The company's revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.